Numerous large-scale epidemiological studies have made it possible to establish a link between the average consumption of table salt (sodium chloride) and blood pressure figures. In France, according to the French Agency for Food, Environmental and Occupational Health & Safety (ANSES), salt intakes could be estimated from 2 national food consumption surveys INCA 1 and INCA 2. This made it possible to take a photograph of food consumption habits and to show that the average consumption of salt contained in food in France is 8.7g/day for men and 6.7g/day for women. To these contributions must also be added 1 to 2g of salt for the resalting and the cooking water. According to the food consumption survey INCA 3, french plate still contains a large part of processed foods and still a little too much salt (on average 9g/day for men and 7g/day for women at compare with the objectives of the National Health Nutrition Program of 8g/day and 6.5g/day respectively). In addition, the World Health Organization (WHO) recommends consuming less than 5g of salt per day.

In this context, sodium intake through mineral water was also questioned. Both in terms of basic and clinical research, the biological effects of dietary sodium chloride intake have been the subject of a great deal of work for several decades. The mechanisms of transmission in the induced or hemodynamic effects related to the absorption of Na multiple debates and their impact on cardiovascular risks remain very uncertain. Work has shown that all subjects do not react homogeneously to sodium chloride intakes, thus determining what are called "NaCl-sensitive" people who in a situation of major sodium intake will show an increase of peripheral vascular resistance and an increase in blood pressure, much more marked than in subjects called " NaCl resistant ".

"NaCl-sensitive" people represent 10 to 30% of the population, with notable differences according to ethnic origins, regions and continents. A marked overrepresentation of this phenotype is observed in patients with hypertension or with a family history of hypertension.

Furthermore, studies conducted on animals and humans show that sodium intake does not have the same impact on the parameters mentioned above, depending on whether it is in the form of chloride or bicarbonate salt.

On the basis of these elements, the investigators developed a clinical study protocol intended to demonstrate a possible differential effect in the biological effects of the same sodium orally intake (2.56g per day), depending on the salt origin.

This single-center, randomized study, aim to determine the difference in absorption between sodium depending on its nature: bicarbonate (NaHCO3) or chloride (NaCl), and the effect of those types of sodium on blood pressure.

In order to realize it, 206 volunteers will be include to assess whether or not they are a "NaCl sensitive volunteer" phenotype.

The study will be carried out on 34 of NaCl sensitive volunteer which will take the sodium dietary supplements. The 2 dietary supplements are table salt (sachet) or bottled water. They will be test in a cross-over design during 2 periods of 1 week separated from 1 week of a washing-out period.

The primary objective will be to compare mean arterial pressure (MAP) resulting from daily supplementation of 2.56 g of sodium (111 mmol), in addition to the food intake of a low-sodium diet from V2 to the end of the study (<5g of NaCl / day), for 7 days, either as sodium chloride or as sodium bicarbonate in hypertensive subjects.

This clinical trial will be separated in 2 phases:

1. Phenotyping (4 visits): to determine if the volunteer is "NaCl sensitive volunteer" or not

   1. V1 (day -28/D-28) = inclusion and beginning of phenotyping phase,
   2. V2 (day -21/D-21) = start of a low-sodium diet (<5g of NaCl / day),
   3. V3 (day -14/D-14) = daily supplementation of sodium chloride for 7 days (9.78g/day),
   4. V4 (day -7/D-7) = "NaCl sensitive volunteer" assessment, end of study for "NaCl non-senstive volunteers".

2. Treatment period for "NaCl sensitive volunteer" with dietary supplement intake in a cross-over design:

   1. PC1 (day 0/D0) = beginning of treatment period 1,
   2. PC2 (day 3/D3) = volunteer contact to make sure he is all right,
   3. V5 (day 7/D7) = end treatment period 1,
   4. PC3 (day 14/D14) = beginning of treatment period 2,
   5. PC4 (day 17/D17) = volunteer contact to make sure he is all right,
   6. V6 (day 21/D21) = end of treatment period 2 and of the study.

The protocol includes a total of 6 visits to PIC/CIC Inserm 1405 of the Clermont-Ferrand University Hospital.

The maximum duration of the study will be of 7 weeks.

Inclusion Criteria:

• Systolic blood pressure between 135-160 mmHg and diastolic 85-100 in self-measurement, untreated or treated but not balanced under treatment,
• Father or mother hypertensive,
• Weight ≥ 50 kg
• Absence of known heart disease,
• Brachialis perimeter between 22 and 42 cm,
• Creatinine clearance within the standards dating from less than 12 months, (GFR> 60ml / min / 1.73m²),
• Agreeing to drink sparkling water during one of the study periods,
• Effective contraception for female subjects of childbearing age,
• Cooperation and understanding sufficient to comply with the requirements of the test,
• Affiliated with a Social Security scheme,
• Agreeing to give written consent,
• Registration or acceptance of registration in the national register of volunteers participating in research.

Exclusion Criteria:

• Consumption of more than 5g/day of salt in the protocol diet (evaluated by natriuresis analyzed in V3)
• Systemic corticosteroid therapy
• Taking prohibited drugs (see list) and at the judgment of the investigator.
• Suffering from pulmonary hypertension
• Woman of childbearing age not using an effective contraceptive method, pregnant or breastfeeding woman,
• History of cardiomyopathy or ischemic heart disease,
• Absence of sinus rhythm,
• Renal failure (DFG <60 ml/min/1.73m²),
• Comorbidity incompatible with the study,
• BMI> 35 kg/m2,
• Disabling cognitive disorders,
• Anxiety when taking measurements alone at home at the judgment of the investigator,
• Diabetes (Type I and II)
• Chronic alcoholism,
• Sports activity deemed to be intense (more than 3 hours / week of intense sport),
• Extreme sweating activity (Sauna, Hammam),
• During participation in another clinical trial, or in the exclusion period, or having received a total amount of compensation greater than 4,500 euros over the 12 months preceding the start of the trial,
• Benefiting from a legal protection measure (curatorship, guardianship, deprived of freedoms, safeguard of justice)
• Not affiliated with the French Social Security scheme.
• Any history deemed significant by the investigator.